Coherus BioSciences

@Coherus_Bio

Leader in developing and commercializing high-quality biosimilar therapeutics.

Vrijeme pridruživanja: veljača 2017.

Tweetovi

Blokirali ste korisnika/cu @Coherus_Bio

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @Coherus_Bio

  1. . President Juliana Reed: “Despite the tough political climate, Congress has rightfully recognized that increasing access to biosimilars is a necessary part of the solution to America’s rising health care costs.”

    Poništi
  2. Our President, CEO & Chairman, Denny Lanfear, on recent efforts from the and to deter anti-competitive practices in the biologics market.

    Poništi
  3. 4. velj

    A panel at the Specialty Therapies and Biosimilars Congress discussed the keys to a successful launch. Developing a long-range marketing strategy to build trust was one of the takeaways shared by the participants. More here:

    Poništi
  4. 3. velj

    "At some point, you simply have an event which causes a tectonic shift in thinking,” said Denny Lanfear, President & CEO, on the rising cost of healthcare. Coherus drives down drug costs through market competition. More here:

    Poništi
  5. 31. sij

    As of December 2019, the has approved 27 , and 12 are currently on the market. Learn more about the rigorous approval process and why experts believe there will be a large uptake of biosimilars in upcoming years:

    Poništi
  6. 30. sij

    "These strong approval figures demonstrate biopharmaceutical companies' unwavering commitment to developing innovative treatments for patients," says from , while discussing the innovative medicines approved in 2019.

    Poništi
  7. 29. sij

    With an average cost of 26% less than their reference products, could provide up to $150B in savings over the next decade, notes @USBiosimilar President Juliana Reed in a recent op-ed. Read more:

    Poništi
  8. 28. sij

    have struggled to gain traction in the U.S. despite widespread adoption in Europe. Experts take recent successful launches as a positive sign for the biosimilar market overall in 2020. More:

    Poništi
  9. 28. sij

    Chip Davis, President & CEO of sees "fearmongering about the quality of biosimilars" perception and lobbying efforts as reasons for slow uptake in the U.S. By enacting incentives for , usage will increase.

    Poništi
  10. 28. sij

    : Gillian Woollett, MA, DPhil, Senior Vice President at Avalere Health, discuss recommended changes for the development and approval process of .

    Poništi
  11. 27. sij

    Patent reform can help compete and deliver savings to the healthcare system. Matthew Lane, Executive Director of the , argues these reforms should be a bipartisan issue. More here:

    Poništi
  12. 24. sij

    The market is expected to expand in the coming years as many reference drugs will soon lose patent exclusivity. By 2026, could save as much as $150 billion according to a recent article in . More:

    Poništi
  13. 23. sij

    : , COO of Pontchartrain Cancer Center: "The availability of introduces competition based on price, offering a lower-cost alternative in the short term and helping to restrict—or even reverse—longer-term price growth."

    Poništi
  14. 22. sij

    #2020 is an exciting year for as more drugs become regulated under the Biologics Price Competition and Innovation Act (BPCIA). Get up to speed on what's to come for in the new year from :

    Poništi
  15. 21. sij

    "Biosimilars are going to be here to stay in my opinion, and it's going to be a great opportunity for community oncology" said Tesh Khullar, Senior Vice President and Advisor, Flatiron Health in a recent video. Watch here:

    Poništi
  16. 21. sij

    In 2017, estimated that biosimilars could save the healthcare system up to $150B from 2017 - 2027. Read the full report on the potential cost-saving benefits of biosimilars.

    Poništi
  17. 17. sij

    ., COO of Pontchartrain Cancer Center called on payers to reject attempts to block biosimilar access and allow physicians to "prescribe as they know best." Doing so, she argues, will allow to fight financial toxicity. More:

    Poništi
  18. 17. sij

    Read up on the top-five developments in the biosimilars industry last year from :

    Poništi
  19. 16. sij

    Dr. Julie R. Gralow, Clinical Director, Breast Medical Oncology at and Professor of Medical Oncology at School of Medicine, discussed role for breast cancer in a recent interview with .

    Poništi
  20. 15. sij

    Read up on the biggest legal developments for U.S. in 2019 from :

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·